Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)

Nyssen, Olga P.Vaira, DinoSaracino, Ilaria MariaFiorini, GiuliaCaldas, MaríaBujanda, LuisPellicano, RinaldoKeco-Huerga, AlmaPabón-Carrasco, ManuelSusanibar, Elida OblitasDi Leo, AlfredoLosurdo, GiuseppePérez-Aísa, ÁngelesGasbarrini, AntonioBoltin, DoronSmith, SineadPhull, PerminderRokkas, TheodoreLamarque, DominiqueCano-Català, AnnaPuig, IgnasiMégraud, FrancisO’morain, ColmGisbert, Javier P.2022-11-042022-11-042022-03-16Nyssen, O P, Vaira, D, Saracino, I M, Fiorini, G, Caldas, M, Bujanda, L, Pellicano, R, Keco-Huerga, A, Pabón-Carrasco, M, Susanibar, E O, Di Leo, A, Losurdo, G, Pérez-Aísa, Á, Gasbarrini, A, Boltin, D, Smith, S, Phull, P, Rokkas, T, Lamarque, D, Cano-Català, A, Puig, I, Mégraud, F, O’morain, C & Gisbert, J P 2022, 'Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)', Journal of Clinical Medicine, vol. 11, no. 6, 1658. https://doi.org/10.3390/jcm110616582077-0383ORCID: /0000-0002-1296-3803/work/183072929https://hdl.handle.net/2164/19467Funding Information: Conflicts of Interest: Gisbert has served as speaker, consultant, and advisory member for or has received research funding from Mayoly, Allergan, Diasorin, Gebro Pharma, and Richen. Nyssen has received research funding from Mayoly and Allergan. Pérez-Aisa has received compensation from Allergan and Mylan for formative actions. A. Di Leo served as consultant for T.H.D. spa. The remaining authors declare no conflict of interest. Funding Information: Funding: This project was promoted and funded by the European Helicobacter and Microbiota Study Group (EHMSG), the Spanish Association of Gastroenterology (AEG) and the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Funding Information: This project was promoted and funded by the European Helicobacter and Microbiota Study Group (EHMSG), the Spanish Association of Gastroenterology (AEG) and the Centro de Investigaci?n Biom?dica en Red de Enfermedades Hep?ticas y Digestivas (CIBERehd). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.1531117engBismuthCultureEradication failureH. pyloriHelicobacter pyloriHp-EuRegRescueRifabutinTreatmentR MedicineGeneral MedicineRExperience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)Journal article10.3390/jcm11061658http://www.scopus.com/inward/record.url?scp=85126625869&partnerID=8YFLogxK116